Fostamatinib (R788) is the first SYK inhibitor tested in clinical phase I/II study for the treatment of B-cell lymphomas, and shows effective therapeutic action, indicating that SYK inhibition could be a novel therapeutic approach in cancer treatment [9, 10]. The gene discussed is SYK; the disease is B-cell non-Hodgkin lymphoma.